BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- aTyr Pharma (LIFE) Reports Q3 EPS of $0.53; Offers Guidance
- Hinge Health, Inc. (HNGE) Tops Q3 EPS by 6c, raises Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
